Salt Lake City, Utah – LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level, recently announced financial results for its second fiscal quarter ended December 31, 2025.
Second Quarter Fiscal 2026 Summary*:
Revenue was $48.9 million, a decrease of 27.8% from the prior year period. Revenue was up 2.9% sequentially from the first quarter.
Revenue in the Americas decreased 32.6%, and revenue in Asia/Pacific & Europe decreased 2.1%.
Net income per diluted share was $0.02, versus $0.19 per diluted share a year ago;
Adjusted earnings per diluted share was $0.15, compared to $0.22 a year ago; and
Adjusted EBITDA was $3.9 million compared to $6.5 million a year ago.
* All comparisons are on a year over year basis and compare the second quarter of fiscal 2026 to the second quarter of fiscal 2025, unless otherwise noted.
Steve Fife, President and CEO of LifeVantage said:
“The second quarter reflected challenging competitive dynamics in the weight loss market as we cycled the launch of our MindBody GLP-1 System™ in October 2024.
We acknowledge that our performance during the quarter did not meet your expectations or ours and we are redoubling our efforts to stabilize our GLP-1 business and make the other changes necessary to return to